Literature DB >> 12208741

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Ryohei Furumai1, Akihisa Matsuyama, Nobuyuki Kobashi, Kun-Hyung Lee, Makoto Nishiyama, Hidenori Nakajima, Akito Tanaka, Yasuhiko Komatsu, Norikazu Nishino, Minoru Yoshida, Sueharu Horinouchi.   

Abstract

FK228 is a histone deacetylase (HDAC) inhibitor, the molecular mechanism of inhibition of which has been unknown. Here we show that reduction of an intramolecular disulfide bond of FK228 greatly enhanced its inhibitory activity and that the disulfide bond was rapidly reduced in cells by cellular reducing activity involving glutathione. Computer modeling suggests that one of the sulfhydryl groups of the reduced form of FK228 (redFK) interacts with the active-site zinc, preventing the access of the substrate. HDAC1 and HDAC2 were more strongly inhibited by redFK than HDAC4 and HDAC6. redFK was less active than FK228 in inhibiting in vivo HDAC activity, due to rapid inactivation in medium and serum. Thus, FK228 serves as a stable prodrug to inhibit class I enzymes and is activated by reduction after uptake into the cells. The glutathione-mediated activation also implicates its clinical usefulness for counteracting glutathione-mediated drug resistance in chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208741

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  216 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 3.  The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.

Authors:  Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

4.  New insights into the genetic organization of the FK228 biosynthetic gene cluster in Chromobacterium violaceum no. 968.

Authors:  Vishwakanth Y Potharla; Shane R Wesener; Yi-Qiang Cheng
Journal:  Appl Environ Microbiol       Date:  2010-12-23       Impact factor: 4.792

5.  Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from Burkholderia thailandensis E264.

Authors:  Cheng Wang; Creston J Flemming; Yi-Qiang Cheng
Journal:  Medchemcomm       Date:  2012-08-01       Impact factor: 3.597

Review 6.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

9.  A backup plan for self-protection: S-methylation of holomycin biosynthetic intermediates in Streptomyces clavuligerus.

Authors:  Bo Li; Ry R Forseth; Albert A Bowers; Frank C Schroeder; Christopher T Walsh
Journal:  Chembiochem       Date:  2012-10-24       Impact factor: 3.164

Review 10.  Genome-guided discovery of diverse natural products from Burkholderia sp.

Authors:  Xiangyang Liu; Yi-Qiang Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2013-11-09       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.